Products with Anticancer Bioactivity

Explore BioCrick products associated with Anticancer biological activity, including catalog numbers, product names and available bioactivity information.

Cat. No.	Product Name
BCN3823	Methyl gallate
Methyl Gallate is a plant polyphenol with antioxidant, anticancer, anti-bacterial, and anti-inflammatory activities.Methyl gallate is a potent and highly specific inhibitor of herpes simplex virus in vitro. Methyl gallate also has a dual cyclooxygenase-2/5-lipoxygenase inhibitory activity. Methyl gallate can inhibit the growth of oral pathogens and S. mutans biofilm formation, and may be used to prevent the formation of oral biofilms.
BCN3835	Kukoamine A
1. Kukoamine A shows hypotensive activity.
BCN3840	Diallyl disulfide
Diallyl disulfide has antitumor effect, the effect can be enhanced by miR-200b and miR-22. Diallyl disulfide induces antioxidant defense mechanism by activating Nrf2 pathway and reduces inflammatory response by inhibiting NF-κB activation. Diallyl disulfide also has protective effect against CP-induced developmental toxicity.
BCN3861	Polygalacin D
1. Polygalacin D can inhibit the expression of lipopolysaccharide (LPS)-induced iNOS and COX-2 protein and mRNA without an appreciable cytotoxic effect on RAW 264.7 macrophages, and can suppress induction by LPS of pro-inflammatory cytokines such as prostaglandin E2 (PGE2). 2. Polygalacin D2 exhibits significant inhibition on the proliferation of five kinds of cultured human tumor cell lines, i. e., A549 (non-small cell lung), SK-OV-3 (ovary), SK-MEL-2 (melanoma), XF498 (central nerve system) and HCT-15 (colon), in vitro. 3. Polygalacin D shows hepatoprotective activities against HSC-T6 cell line in vitro.
BCN3862	Escin IA
Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.

Anticancer Bioactivity Products